0001651308-21-000126.txt : 20210621 0001651308-21-000126.hdr.sgml : 20210621 20210621164553 ACCESSION NUMBER: 0001651308-21-000126 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210616 FILED AS OF DATE: 20210621 DATE AS OF CHANGE: 20210621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Huang Jane CENTRAL INDEX KEY: 0001683913 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 211031379 MAIL ADDRESS: STREET 1: C/O MOURANT OZANNES CORPORATE SERVICES STREET 2: 94 SOLARIS AVENUE CITY: CAMANA BAY, GRAND CAYMAN STATE: E9 ZIP: KY1-1108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981209416 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 4 1 wf-form4_162430832547020.xml FORM 4 X0306 4 2021-06-16 0 0001651308 BeiGene, Ltd. BGNE 0001683913 Huang Jane C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9 KY1-1108 CAYMAN ISLANDS 0 1 0 0 CMO, Hematology Ordinary Shares 2021-06-16 4 A 0 25350 0 A 304186 D American Depositary Shares 2021-06-18 4 S 0 469 325.6568 D 0 D Share Option (Right to Buy) 26.53 2021-06-16 4 A 0 157196 0 A 2031-06-15 Ordinary Shares 157196.0 157196 D Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Each American Depositary Share ("ADS") represents 13 Ordinary Shares. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. /s/ Qing Nian, as Attorney-in-Fact 2021-06-21